Skip to main content
Top
Published in: European Archives of Psychiatry and Clinical Neuroscience 2/2015

01-03-2015 | Original Paper

What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial

Authors: Rebecca Schennach, Michael Riedel, Michael Obermeier, Ilja Spellmann, Richard Musil, Markus Jäger, Max Schmauss, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G. Schmidt, Wolfgang Gaebel, Joachim Klosterkötter, Isabella Heuser, Wolfgang Maier, Matthias R. Lemke, Eckart Rüther, Stefan Klingberg, Markus Gastpar, Hans-Jürgen Möller

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 2/2015

Login to get access

Abstract

The aim of this study was to evaluate residual symptoms in patients achieving remission according to the consensus criteria and to analyze their potential influence on the patient’s outcome one year after discharge. In total, 399 patients suffering from a schizophrenia spectrum disorder were evaluated within a naturalistic study. Remission status was examined using the consensus criteria. Residual symptoms were defined as any symptom present at the time-point of remission following analogous analyses performed in depressed patients. Therefore, a PANSS item with a symptom severity of >1 (= at least borderline mentally ill) was defined to be a residual symptom. Remitters with and without residual symptoms were compared regarding psychopathology, functioning and side effects. In total, 236 patients (59 %) were remitters at discharge with 94 % of them suffering from at least one residual symptom. The most common residual symptoms were blunted affect (49 %), conceptual disorganization (42 %) and social withdrawal (40 %). A significant association was found between the presence of residual symptoms and the severity of side effects (p < 0.0001) and functioning (p = 0.0003) at discharge as well as between residual symptoms and the risk of relapse and chance of remission one year after discharge. Residual symptoms were highly prevalent in remitted schizophrenia inpatients following the suggested definition. Most residual symptoms were persistent baseline symptoms suggesting an ongoing illness severity. Also, the necessity to re-evaluate the consensus criteria questioning the status of remission in these patients is also pointed out.
Literature
1.
go back to reference Nasrallah HA, Lasser R (2006) Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol 20:57–61CrossRefPubMed Nasrallah HA, Lasser R (2006) Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol 20:57–61CrossRefPubMed
2.
go back to reference Schennach-Wolff R, Moller HJ, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Riedel M (2010) A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials. Pharmacopsychiatry 43:245–251 Schennach-Wolff R, Moller HJ, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Riedel M (2010) A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials. Pharmacopsychiatry 43:245–251
3.
go back to reference Karow A, Naber D, Lambert M, Moritz S (2011) Remission as perceived by people with schizophrenia, family members and psychiatrists. Eur Psychiatry (In Press) Karow A, Naber D, Lambert M, Moritz S (2011) Remission as perceived by people with schizophrenia, family members and psychiatrists. Eur Psychiatry (In Press)
4.
go back to reference Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, Miyahara S, Rush AJ (2010) Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 40:41–50CrossRefPubMed Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, Miyahara S, Rush AJ (2010) Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 40:41–50CrossRefPubMed
5.
go back to reference Gross G, Huber G (2008) Psychopathology of schizophrenia and brain imaging. Fortschr Neurol Psychiatr 76(Suppl 1):S49–S56 Gross G, Huber G (2008) Psychopathology of schizophrenia and brain imaging. Fortschr Neurol Psychiatr 76(Suppl 1):S49–S56
6.
go back to reference Paykel ES (1998) Remission and residual symptomatology in major depression. Psychopathology 31:5–14CrossRefPubMed Paykel ES (1998) Remission and residual symptomatology in major depression. Psychopathology 31:5–14CrossRefPubMed
7.
go back to reference Wolwer W, Buchkremer G, Hafner H, Klosterkotter J, Moller HJ, Maier W, Gaebel W (2003) German research network on schizophrenia-bridging the gap between research and care. Eur Arch Psychiatry Clin Neurosci 253:321–329CrossRefPubMed Wolwer W, Buchkremer G, Hafner H, Klosterkotter J, Moller HJ, Maier W, Gaebel W (2003) German research network on schizophrenia-bridging the gap between research and care. Eur Arch Psychiatry Clin Neurosci 253:321–329CrossRefPubMed
8.
go back to reference Jager M, Riedel M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, Kuhn KU, Lemke MR, Ruther E, Buchkremer G, Gastpar M, Bottlender R, Strauss A, Moller HJ (2007) Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 257:47–53 Jager M, Riedel M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, Kuhn KU, Lemke MR, Ruther E, Buchkremer G, Gastpar M, Bottlender R, Strauss A, Moller HJ (2007) Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 257:47–53
9.
go back to reference American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington
10.
go back to reference Cording C (1998) Conceptual aspects in development and implementation of basic psychiatric documentation. Psychiatr Prax 25:175–178PubMed Cording C (1998) Conceptual aspects in development and implementation of basic psychiatric documentation. Psychiatr Prax 25:175–178PubMed
11.
go back to reference Kay SR, Opler LA, Lindenmayer JP (1988) Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23:99–110CrossRefPubMed Kay SR, Opler LA, Lindenmayer JP (1988) Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23:99–110CrossRefPubMed
12.
go back to reference Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100 Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100
13.
go back to reference Andreasen NC, Carpenter WT, Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441–449 Andreasen NC, Carpenter WT, Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441–449
14.
go back to reference Seemüller F, Riedel M, Obermeier M, Golstein-Müller B, Adli M, Bauer M, Kronmuller K, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Möller H-J (2011) Clinical description and 1-year persistence of residual symptoms in a large naturalistic sample of remitted depressed inpatients (Unpublished Work) Seemüller F, Riedel M, Obermeier M, Golstein-Müller B, Adli M, Bauer M, Kronmuller K, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Möller H-J (2011) Clinical description and 1-year persistence of residual symptoms in a large naturalistic sample of remitted depressed inpatients (Unpublished Work)
16.
go back to reference Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D (2006) Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res 86:300–308CrossRefPubMed Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D (2006) Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res 86:300–308CrossRefPubMed
17.
go back to reference Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D (2010) Remission in schizophrenia: its validity, frequency, predictors and patients’ perspective 5 years after. Dialog Clin Neurosci (in press) Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D (2010) Remission in schizophrenia: its validity, frequency, predictors and patients’ perspective 5 years after. Dialog Clin Neurosci (in press)
18.
go back to reference Beitinger R, Lin J, Kissling W, Leucht S (2008) Comparative remission rates of schizophrenic patients using various remission criteria. Prog Neuropsychopharmacol Biol Psychiatry 32:1643–1651 Beitinger R, Lin J, Kissling W, Leucht S (2008) Comparative remission rates of schizophrenic patients using various remission criteria. Prog Neuropsychopharmacol Biol Psychiatry 32:1643–1651
19.
go back to reference David A, Van OJ, Jones P, Harvey I, Foerster A, Fahy T (1995) Insight and psychotic illness. Cross-sectional and longitudinal associations. Br J Psychiatry 167:621–628 David A, Van OJ, Jones P, Harvey I, Foerster A, Fahy T (1995) Insight and psychotic illness. Cross-sectional and longitudinal associations. Br J Psychiatry 167:621–628
20.
go back to reference Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA (2009) Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 35:336–346CrossRefPubMedCentralPubMed Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA (2009) Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 35:336–346CrossRefPubMedCentralPubMed
21.
go back to reference Helldin L, Kane JM, Karilampi U, Norlander T, Archer T (2006) Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res 40:738–745 Helldin L, Kane JM, Karilampi U, Norlander T, Archer T (2006) Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res 40:738–745
22.
go back to reference Kane JM, Crandall DT, Marcus RN, Eudicone J, Pikalov A III, Carson WH, Swyzen W (2007) Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 95:143–150CrossRefPubMed Kane JM, Crandall DT, Marcus RN, Eudicone J, Pikalov A III, Carson WH, Swyzen W (2007) Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 95:143–150CrossRefPubMed
23.
go back to reference Alptekin K, Erkoc S, Gogus AK, Kultur S, Mete L, Ucok A, Yazici KM (2005) Disability in schizophrenia: clinical correlates and prediction over 1-year follow-up. Psychiatry Res 135:103–111 Alptekin K, Erkoc S, Gogus AK, Kultur S, Mete L, Ucok A, Yazici KM (2005) Disability in schizophrenia: clinical correlates and prediction over 1-year follow-up. Psychiatry Res 135:103–111
24.
go back to reference Saravanan B, Jacob KS, Johnson S, Prince M, Bhugra D, David AS (2010) Outcome of first-episode schizophrenia in India: longitudinal study of effect of insight and psychopathology. Br J Psychiatry 196:454–459 Saravanan B, Jacob KS, Johnson S, Prince M, Bhugra D, David AS (2010) Outcome of first-episode schizophrenia in India: longitudinal study of effect of insight and psychopathology. Br J Psychiatry 196:454–459
25.
go back to reference Bora E, Gokcen S, Kayahan B, Veznedaroglu B (2008) Deficits of social-cognitive and social-perceptual aspects of theory of mind in remitted patients with schizophrenia: effect of residual symptoms. J Nerv Ment Dis 196:95–99CrossRefPubMed Bora E, Gokcen S, Kayahan B, Veznedaroglu B (2008) Deficits of social-cognitive and social-perceptual aspects of theory of mind in remitted patients with schizophrenia: effect of residual symptoms. J Nerv Ment Dis 196:95–99CrossRefPubMed
26.
go back to reference Alenius M, Hammarlund-Udenaes M, Hartvig P, Sundquist S, Lindstrom L (2009) Treatment response in psychotic patients classified according to social and clinical needs, drug side effects, and previous treatment; a method to identify functional remission. Compr Psychiatry 50:453–462CrossRefPubMed Alenius M, Hammarlund-Udenaes M, Hartvig P, Sundquist S, Lindstrom L (2009) Treatment response in psychotic patients classified according to social and clinical needs, drug side effects, and previous treatment; a method to identify functional remission. Compr Psychiatry 50:453–462CrossRefPubMed
27.
go back to reference Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB (1998) A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55:694–700CrossRefPubMed Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB (1998) A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55:694–700CrossRefPubMed
28.
go back to reference Fava M (2006) Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol 20:29–34CrossRefPubMed Fava M (2006) Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol 20:29–34CrossRefPubMed
29.
go back to reference Chabungbam G, Avasthi A, Sharan P (2007) Sociodemographic and clinical factors associated with relapse in schizophrenia. Psychiatry Clin Neurosci 61:587–593CrossRefPubMed Chabungbam G, Avasthi A, Sharan P (2007) Sociodemographic and clinical factors associated with relapse in schizophrenia. Psychiatry Clin Neurosci 61:587–593CrossRefPubMed
30.
go back to reference Haro JM, Novick D, Suarez D, Alonso J, Lepine JP, Ratcliffe M (2006) Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 26:571–578CrossRefPubMed Haro JM, Novick D, Suarez D, Alonso J, Lepine JP, Ratcliffe M (2006) Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 26:571–578CrossRefPubMed
31.
go back to reference Tandon R, Nasrallah HA, Keshavan MS (2009) Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res 110:1–23 Tandon R, Nasrallah HA, Keshavan MS (2009) Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res 110:1–23
32.
go back to reference Moller HJ, Jager M, Riedel M, Obermeier M, Strauss A, Bottlender R (2010) The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. Eur Arch Psychiatry Clin Neurosci 260:367–384CrossRefPubMed Moller HJ, Jager M, Riedel M, Obermeier M, Strauss A, Bottlender R (2010) The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. Eur Arch Psychiatry Clin Neurosci 260:367–384CrossRefPubMed
33.
go back to reference Ribeiro SC, Tandon R, Ricoy R, Mazzara C, Craig KA, Greden JF (1992) Clinical predictors of 1-year outcome in schizophrenia. Psychopathology 25:331–334CrossRefPubMed Ribeiro SC, Tandon R, Ricoy R, Mazzara C, Craig KA, Greden JF (1992) Clinical predictors of 1-year outcome in schizophrenia. Psychopathology 25:331–334CrossRefPubMed
34.
go back to reference Chang WC, Hui CL, Tang JY, Wong GH, Lam MM, Chan SK, Chen EY (2011) Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr Res 133:22–28CrossRefPubMed Chang WC, Hui CL, Tang JY, Wong GH, Lam MM, Chan SK, Chen EY (2011) Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr Res 133:22–28CrossRefPubMed
36.
go back to reference Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS (2013) Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol 23:196–204 Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS (2013) Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol 23:196–204
37.
go back to reference Leifker FR, Bowie CR, Harvey PD (2009) Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms. Schizophr Res 115:82–87CrossRefPubMed Leifker FR, Bowie CR, Harvey PD (2009) Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms. Schizophr Res 115:82–87CrossRefPubMed
38.
go back to reference Henmi Y (1993) Prodromal symptoms of relapse in schizophrenic outpatients: retrospective and prospective study. Jpn J Psychiatry Neurol 47:753–775PubMed Henmi Y (1993) Prodromal symptoms of relapse in schizophrenic outpatients: retrospective and prospective study. Jpn J Psychiatry Neurol 47:753–775PubMed
39.
go back to reference Zisook S, McAdams LA, Kuck J, Harris MJ, Bailey A, Patterson TL, Judd LL, Jeste DV (1999) Depressive symptoms in schizophrenia. Am J Psychiatry 156:1736–1743 Zisook S, McAdams LA, Kuck J, Harris MJ, Bailey A, Patterson TL, Judd LL, Jeste DV (1999) Depressive symptoms in schizophrenia. Am J Psychiatry 156:1736–1743
40.
go back to reference Chan GW, Ungvari GS, Shek DT, Leung Dagger JJ (2003) Hospital and community-based care for patients with chronic schizophrenia in Hong Kong–quality of life and its correlates. Soc Psychiatry Psychiatr Epidemiol 38:196–203CrossRefPubMed Chan GW, Ungvari GS, Shek DT, Leung Dagger JJ (2003) Hospital and community-based care for patients with chronic schizophrenia in Hong Kong–quality of life and its correlates. Soc Psychiatry Psychiatr Epidemiol 38:196–203CrossRefPubMed
Metadata
Title
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial
Authors
Rebecca Schennach
Michael Riedel
Michael Obermeier
Ilja Spellmann
Richard Musil
Markus Jäger
Max Schmauss
Gerd Laux
Herbert Pfeiffer
Dieter Naber
Lutz G. Schmidt
Wolfgang Gaebel
Joachim Klosterkötter
Isabella Heuser
Wolfgang Maier
Matthias R. Lemke
Eckart Rüther
Stefan Klingberg
Markus Gastpar
Hans-Jürgen Möller
Publication date
01-03-2015
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Psychiatry and Clinical Neuroscience / Issue 2/2015
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-014-0528-2

Other articles of this Issue 2/2015

European Archives of Psychiatry and Clinical Neuroscience 2/2015 Go to the issue